AbbVie
ABBV
#25
Rank
NZ$691.49 B
Marketcap
NZ$391.25
Share price
0.39%
Change (1 day)
27.25%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

Earnings for AbbVie (ABBV)

Earnings in 2025 (TTM): NZ$2.68 Billion

According to AbbVie's latest financial reports the company's current earnings are NZ$59.64 Billion. In 2024 the company made an earning of NZ$6.35 Billion a decrease over its 2023 earnings that were of NZ$10.68 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for AbbVie from 2011 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) NZ$2.68 B-57.69%
2024 NZ$6.35 B-40.54%
2023 NZ$10.68 B-53.62%
2022 NZ$23.04 B3.76%
2021 NZ$22.21 B282.25%
2020 NZ$5.81 B-59.67%
2019 NZ$14.40 B62.13%
2018 NZ$8.88 B-32.74%
2017 NZ$13.21 B-1.99%
2016 NZ$13.48 B18.65%
2015 NZ$11.36 B180.5%
2014 NZ$4.05 B-55.57%
2013 NZ$9.11 B-6.86%
2012 NZ$9.79 B56.05%
2011 NZ$6.27 B

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Pfizer
PFE
NZ$20.26 B 613.98%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$13.73 B 383.92%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$38.48 B 1,255.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$14.09 B 396.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$16.90 B 495.54%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$3.25 B 14.70%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
NZ$15.94 B 461.62%๐Ÿ‡ฌ๐Ÿ‡ง UK
AstraZeneca
AZN
NZ$22.38 B 688.55%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$0.99 B-64.87%๐Ÿ‡บ๐Ÿ‡ธ USA